viewValiRx PLC

ValiRx agrees break fee as it terminates financing agreement

ValiRx will pay a break fee of £212,500 to European High Growth Opportunities SF after the pair agreed to terminate the financing deal

The two parties entered into the subscription agreement at the end of April

Drug developer ValiRx Plc (LON:VAL) has agreed to terminate a financing agreement with European High Growth Opportunities Securitisation Fund.

As part of the deal, ValiRx is paying the investor a £212,500 break fee; slightly higher than the £150,000 bosses had previously expected.

The fee will be paid in shares issued at the lowest closing price during the five days prior to the payment. ValiRx said this would protect its current cash position.

READ: ValiRx raises funds to meet immediate working capital needs

The company reminded investors that a £400,000 tax credit is due next month, while it has also raked in another £150,000 from the sale of an unlisted security.

A recent £300,000 share placing has also helped to top up the coffers.

“As previously announced, the company's working capital position is dependent on new funds being made available to it and it continues to manage its working capital position carefully.”

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares.

ValiRx shares were down 1.7% in late-afternoon trading on Tuesday.

Quick facts: ValiRx PLC

Price: 24.25 GBX

Market: AIM
Market Cap: £14.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...


Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read